<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJOG</journal-id><journal-title-group><journal-title>Open Journal of Obstetrics and Gynecology</journal-title></journal-title-group><issn pub-type="epub">2160-8792</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojog.2023.136087</article-id><article-id pub-id-type="publisher-id">OJOG-125608</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Endocrine-Disrupting Chemicals: Possible Genesis of Ovarian Tumors
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kasonde</surname><given-names>Chanda</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ziwei</surname><given-names>Wang</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Shen</surname><given-names>Ning</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xue</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yingxiao</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China</addr-line></aff><aff id="aff3"><addr-line>China Exposomics Institute (CEI) Precision Medicine Co., Ltd., Shanghai, China</addr-line></aff><aff id="aff1"><addr-line>Department of Obstetrics and Gynecology, Second Affiliated Hospital of Nanjing Medical University, Nanjing, China</addr-line></aff><aff id="aff2"><addr-line>Core Laboratory, Department of Clinical Laboratory, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>06</month><year>2023</year></pub-date><volume>13</volume><issue>06</issue><fpage>1025</fpage><lpage>1037</lpage><history><date date-type="received"><day>31,</day>	<month>May</month>	<year>2023</year></date><date date-type="rev-recd"><day>12,</day>	<month>June</month>	<year>2023</year>	</date><date date-type="accepted"><day>15,</day>	<month>June</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background:
   Prolonged exposure to environmental toxicants like endo
  crine-disrupting chemicals has been linked to several ovarian pathologies.
   Exposure to endocrine-disrupting chemicals may start at any time of life from 
  the 
  fetal stage to adulthood resulting in various health complications<b> </b>The
   purpose of our study is to compare the concentration levels and association of benzopyrene, bisphenol A and genistein in patients with ovarian tumors and normal control group. We also sort to evaluate the predictive performance of benzopyrene, bisphenol A and genistein in patients with ovarian tumors.
   
  <b>Methods:</b>
   A case
  -
  control study was conducted for randomly selected participants in
  volving 30 patients and 30 controls. 30 patients with radiologically diagnosed and histopathological confirmed ovarian tumors were included in the study between January 2022 and December 2022. Urine samples from each group were analyzed using liquid chromatography
  -
  mass spectrometry. Descriptive analysis
   for normally distributed continuous variables was done accordingly. Concentration levels of endocrine-disrupting chemicals w
  ere
   assessed using
   the
   Mann-Whitney test. 
  The 
  association of endocrine-disrupting chemicals
   with pathological ovarian tumors was analyzed using binary logistic regression. Evaluation of the diagnostic performance of endocrine-disrupting chemicals was analyzed using the ROC curve.
   
  <b>Results:</b>
   
  Overall, patients were significantly (P = 0.000) older than the healthy controls. Mean years (SD) w
  ere
   36.7 (7.90)
   and 28.8 years (4.89) for patients and normal women respectively. Endometriomas had the highest incidence of 50%. 
  The
   level of benzopyrene and bis
  phenol A in patients was significantly higher than those in the control group, while the level of genistein was significantly higher in normal controls. Benzopyrene and bisphenol A were significantly associated with ovarian cysts, 
  and the 
  inci
  dence of pathological ovarian cysts was positively correlated to these EDCs, 
  with 
  OR value 64.79 (P = 0.005) for benzopyrene and 9.609 (P = 0.001) for
   bisphenol A. Genistein was significantly negatively correlated with the incidence of pathological ovarian tumors, 
  with
   OR value of 0.153 (P = 0.007). Diagnostic performance on the AUC for benzopyrene, bisphenol A and genistein&amp;l
 
</p></abstract><kwd-group><kwd>Environmental Toxicants</kwd><kwd> Endocrine-Disrupting Chemical</kwd><kwd> Ovarian Cyst</kwd><kwd> Ovarian Tumor</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The actual prevalence of ovarian tumors is unknown, as many patients are believed to have no symptoms and are undiagnosed, but many researchers have reported an incidence of 8% - 18% [<xref ref-type="bibr" rid="scirp.125608-ref1">1</xref>] . Ovarian cysts are divided into 2 main categories, namely physiological and pathological [<xref ref-type="bibr" rid="scirp.125608-ref2">2</xref>] . Physiological ovarian cysts occur as a result of the normal menstrual cycle while the pathological cyst isn’t related to the menstrual cycle. Pathological ovarian cysts are considered as ovarian tumors, which can be benign, malignant and borderline. Benign tumors are more common in young females, but malignant ones are more frequent in elderly women [<xref ref-type="bibr" rid="scirp.125608-ref3">3</xref>] .</p><p>Some of the risk factors for ovarian cysts include infertility treatment [<xref ref-type="bibr" rid="scirp.125608-ref4">4</xref>] , drugs like tamoxifen [<xref ref-type="bibr" rid="scirp.125608-ref5">5</xref>] , pregnancy [<xref ref-type="bibr" rid="scirp.125608-ref6">6</xref>] , maternal gonadotropins [<xref ref-type="bibr" rid="scirp.125608-ref7">7</xref>] , cigarette smoking [<xref ref-type="bibr" rid="scirp.125608-ref8">8</xref>] and tubal ligation [<xref ref-type="bibr" rid="scirp.125608-ref9">9</xref>] . In recent times, the environmental pollution caused by urbanization and industrialization has been reported to affect human health globally [<xref ref-type="bibr" rid="scirp.125608-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.125608-ref11">11</xref>] . These environmental toxicants are chemical compounds in our environment due to various processes, including manufacturing, combustion, leaching from products, and human contamination [<xref ref-type="bibr" rid="scirp.125608-ref12">12</xref>] . Most of the environmental toxicants are known endocrine-disrupting chemicals (EDCs) [<xref ref-type="bibr" rid="scirp.125608-ref13">13</xref>] . EDCs are chemicals or chemical mixtures, which interfere with normal hormone action [<xref ref-type="bibr" rid="scirp.125608-ref14">14</xref>] . This is of concern because women are exposed to EDCs on a daily basis, some EDCs are known to target the ovary and cause reproductive health problems, such as endometriosis, infertility, premature ovarian failure and abnormal sex steroid hormone levels. Exposure to EDCs may occur by ingestion of water, food and dust, via inhalation of gases and air particles and via dermal absorption of cosmetics and/or substances deriving from thermal paper. Breastfeeding and vertical transmission of EDCs have been demonstrated [<xref ref-type="bibr" rid="scirp.125608-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.125608-ref16">16</xref>] .</p><p>The purpose of our study is to compare the concentration levels of EDCs, namely benzo(a)pyrene, bisphenol A and genistein flavone between patients with ovarian tumors and the normal control group. We also sort to evaluate the predictive performance and association of benzo(a)pyrene, bisphenol A and genistein with ovarian tumors.</p></sec><sec id="s2"><title>2. Methodology</title><sec id="s2_1"><title>2.1. Participants</title><p>Randomly selected participants involving 60 participants were involved 30 patients and 30 normal control cases. Ovarian tumor patients who underwent surgery between January 2022 and December 2022 at the Second Affiliated Hospital of Nanjing Medical University were enrolled in the present study. No patients were pregnant, critically ill, on contraceptives 6 months prior to this study or had preoperative chemotherapy, radiotherapy or other treatment history or other inflammatory diseases. The 30 enrolled patients were 18 years and above. All patients had a pelvic ultrasound done for radiological diagnosis of ovarian cyst. The 30 control subjects were healthy volunteers with no current or previous history of ovarian disease.</p></sec><sec id="s2_2"><title>2.2. Eligibility Criteria for Patients</title><sec id="s2_2_1"><title>2.2.1. Inclusion Criteria</title><p>- ≥18 years of age;</p><p>- Admitted female;</p><p>- Patient willing to participate;</p><p>- Ovarian tumor of any size identified by pelvic ultrasound examination;</p><p>- Ovarian tumor biopsy confirmed by histopathology.</p></sec><sec id="s2_2_2"><title>2.2.2. Exclusion Criteria</title><p>- Patients &lt; 18 years of age;</p><p>- Pregnant women;</p><p>- Critically ill patients;</p><p>- Contraceptive therapy within last 6 months prior to presentation;</p><p>- Comorbidities including diabetes mellitus, hypertension, renal dysfunction, polycystic ovarian syndrome, primary ovarian insufficiency or ovarian cysts</p><p>- History of chemotherapy or radiotherapy;</p><p>- Preoperative chemotherapy or radiotherapy.</p></sec></sec><sec id="s2_3"><title>2.3. Eligibility Criteria for Healthy Controls</title><sec id="s2_3_1"><title>2.3.1. Inclusion Criteria</title><p>- ≥18 years of age;</p><p>- Individuals willing to participate in the study;</p><p>- Female individuals;</p><p>- Healthy women coming for routine medical checkups or employees of the hospitals.</p></sec><sec id="s2_3_2"><title>2.3.2. Exclusion Criteria</title><p>- Patients &lt; 18 years of age;</p><p>- Pregnant women;</p><p>- Critically ill patients;</p><p>- Contraceptive therapy within last 6 months prior to presentation;</p><p>- Comorbidities including diabetes mellitus, hypertension, renal dysfunction, polycystic ovarian syndrome, primary ovarian insufficiency or ovarian cysts;</p><p>- History of chemotherapy or radiotherapy;</p><p>- Preoperative chemotherapy or radiotherapy.</p></sec></sec><sec id="s2_4"><title>2.4. Tissue Samples</title><p>The ovarian tissue samples were collected at the time of the curative surgery. Specimens were routinely processed for histopathological assessment to confirm the diagnosis of pathological ovarian cyst.</p></sec><sec id="s2_5"><title>2.5. Urine Samples</title><p>10 ml morning mid-stream urine was collected from each participant and stored at room temperature before laboratory analysis. The samples were pretreated according to the LC/MS/MS common toxin analysis method package. Urine samples (2 ml) was first filtered with a 0.22 μm filter membrane, then added acetic acid-sodium acetate buffer (0.5 M) to adjust the pH value to 5.4, then added β-glucuronidase/arylsulfatase (10 μl) and vitamin C (5 mg), incubate overnight at room temperature to complete the enzymatic hydrolysis reaction. The samples after enzymatic digestion were subjected to solid phase extraction with SPE cartridges (C18 ENVI, 0.25 g). The extract was eluted with methanol (2 ml), dried with nitrogen, and finally redissolved with methanol (100 μl) as the analyte to be tested. 50 μl of the analyte to be tested was transferred to a liquid chromatography vial with a micro syringe for sample analysis. Before analysis of the sample, analytical conditions had to be met:</p><p>1) Liquid phase conditions: Mobile phase: Phase A: (0.1% formic acid + 5 mM ammonium formate) water, Phase B: Acetonitrile, Flow rate: 0.4 mL/min. Column temperature: 40˚C, Chromatographic column: ACQUITY UPLC BEH C18 (1.7 μm, 2.1 &#215; 100 mm), Injection volume: 5 μl and Elution method: Gradient elution, the initial gradient ratio is 30% (Phase B).</p><p>2) Mass Spectrometry Conditions: Ion source: ESI, DL temperature: 250˚C Heating module temperature: 400˚C, Interface temperature: 300˚C, Nebulizing gas flow rate: 2.0 L/min, Drying gas flow rate: 10.0 L/min, Heater tassel: 10.0 L/min, Collision gas: Argon, Scanning mode: MRM.</p><p>3) Characteristic MRM mass spectrum: Analysis of urine was done using the analytical instrument: Shimadzu LCMS-8050CL triple quadrupole liquid mass spectrometry system (registered medical device number: 20182400195) LC-30A system, including LC-30AD &#215; 2 (infusion pump), SIL-30AC (autosampler), CTO-30A (column thermostat), FCV-32AH (high-pressure flow switching valve) CBM-20A (system controller), DGU-20A5 (online degasser) and LabSolutions Ver. 5.60 (chromatographic workstation).</p></sec><sec id="s2_6"><title>2.6. Statistical Analysis</title><p>Statistical analysis was performed using SPSS software version 23 and visualization was done by graph pad prism. Descriptive analysis for frequencies and percentages on continuous variables was done. Independent sample t test was done to compare the means for the two groups. To assess the concentration levels of EDCs we used the Mann-Whitney test analysis. Association of EDCs with pathological ovarian tumors was analyzed using binary logistic regression. Evaluation of the diagnostic performance of EDCs was analyzed using the ROC curve. Confidence interval was set at 95% and P &lt; 0.05 (2-tailed) was considered statistically significant.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Participants Demographic Characteristics</title><p>A total of 60 individuals participated in this study of which 30 had pathological ovarian cyst and the other 30 were normal health women. Overall, majority of the patients were older, and above 40 years old; more overweight, alcohol intake, parity and cigarrete smoking were seen in patients than in normal controls (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Demographic characteristics of patients and normal controls</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variable</th><th align="center" valign="middle" >Overall N = 60</th><th align="center" valign="middle" >Patients N = 30 n (%)</th><th align="center" valign="middle" >Controls N = 30 n (%)</th><th align="center" valign="middle" >P-value</th></tr></thead><tr><td align="center" valign="middle" >Age group (years), mean (SD) 18 - 30 31 - 40 &gt;40</td><td align="center" valign="middle" >32 (53.3) 13 (21.7) 15 (25.0)</td><td align="center" valign="middle" >36.7 (7.90) 8 (26.7) 9 (30.0) 13 (43.3)</td><td align="center" valign="middle" >28.8 (4.89) 24 (80.0) 4 (13.3) 2 (6.7)</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >Parity, mean (SD) 0 1 2 &gt;2</td><td align="center" valign="middle" >23 (38.3) 28 (46.7) 8 (53.3) 1 (1.7)</td><td align="center" valign="middle" >0.87 (0.68) 9 (30.0) 16 (53.3) 4 (13.3) 1 (3.3)</td><td align="center" valign="middle" >0.67 (0.71) 14 (46.7) 12 (40.0) 4 (13.3) 0 (0.0)</td><td align="center" valign="middle" >0.271</td></tr><tr><td align="center" valign="middle" >BMI group (kg/m<sup>2</sup>), mean (SD) &lt;18.5 (underweight) 18.5 - 24.9 (normal) 25 - 29.9 (overweight) ≥30-obese</td><td align="center" valign="middle" >1 (1.7) 48 (80.0) 11 (18.3) 0 (0.0)</td><td align="center" valign="middle" >22.7 (2.9) 1 (3.3) 22 (73.3) 7 (23.3) 0 (0.0)</td><td align="center" valign="middle" >22.4 (2.6) 0 (0.0) 26 (86.7) 4 (13.3) 0 (0.0)</td><td align="center" valign="middle" >0.654</td></tr><tr><td align="center" valign="middle" >Marital status, Married Single</td><td align="center" valign="middle" >41 (68.3) 19 (31.7)</td><td align="center" valign="middle" >29 (96.7) 1 (3.3)</td><td align="center" valign="middle" >12 (40.0) 18 (60.0)</td><td align="center" valign="middle" >NA</td></tr><tr><td align="center" valign="middle" >Alcohol intake Occasionally Never</td><td align="center" valign="middle" >6 (10.0) 54 (90.0)</td><td align="center" valign="middle" >5 (16.7) 25 (83.3)</td><td align="center" valign="middle" >1 (3.3) 29 (96.7)</td><td align="center" valign="middle" >NA</td></tr><tr><td align="center" valign="middle" >Cigarette smoking Occasionally Never</td><td align="center" valign="middle" >2 (3.3) 58 (96.7)</td><td align="center" valign="middle" >2 (6.7) 28 (93.3)</td><td align="center" valign="middle" >0 (0.0) 30 (100)</td><td align="center" valign="middle" >NA</td></tr></tbody></table></table-wrap></sec><sec id="s3_2"><title>3.2. Histopathology of Tissue Samples</title><p>Histopathological data of the 30 patients were analyzed (<xref ref-type="table" rid="table2">Table 2</xref>). Majority of pathological ovarian tumors were Endometriomas (15/30 cases, 50%) with lowest cases being cystadenomas (2/30 cases, 6.7%).</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Histopathological findings of the cases</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Cyst type</th><th align="center" valign="middle" >n (%)</th></tr></thead><tr><td align="center" valign="middle" >Teratomas Endometriomas Cystadenomas</td><td align="center" valign="middle" >13 (43.3) 15 (50.0) 2 (6.7)</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >30 (100)</td></tr></tbody></table></table-wrap></sec><sec id="s3_3"><title>3.3. Urine Concentration of Endocrine-Disrupting Chemicals (EDCs)</title><p>The results of Mann-Whitney test analysis show that the levels of benzopyrene and bisphenol A in patients with ovarian cysts are significantly higher than those in the control group, but the level of genistein is significantly lower than those in the control group (P = 0.001) (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="s3_4"><title>3.4. Association of EDCs with Pathological Ovarian Cysts</title><p>The results of binary logistic regression analysis in <xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="table" rid="table3">Table 3</xref> show</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Binary regression analysis of benzopyrene, bisphenol A and genistein with ovarian cysts</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >B</th><th align="center" valign="middle" >S.E.</th><th align="center" valign="middle" >Wald</th><th align="center" valign="middle" >P-value</th><th align="center" valign="middle" >OR</th><th align="center" valign="middle" >95% lower</th><th align="center" valign="middle" >C.I. for OR upper</th></tr></thead><tr><td align="center" valign="middle" >Benzopyrene (pg/mL) 4.171</td><td align="center" valign="middle" >1.483</td><td align="center" valign="middle" >7.913</td><td align="center" valign="middle" >0.005</td><td align="center" valign="middle" >64.799</td><td align="center" valign="middle" >3.543</td><td align="center" valign="middle" >1185.257</td></tr><tr><td align="center" valign="middle" >Bisphenol A (ng/mL) 2.263</td><td align="center" valign="middle" >0.664</td><td align="center" valign="middle" >11.611</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >9.609</td><td align="center" valign="middle" >2.615</td><td align="center" valign="middle" >35.312</td></tr><tr><td align="center" valign="middle" >Genistein (ng/mL) −1.879</td><td align="center" valign="middle" >0.692</td><td align="center" valign="middle" >7.378</td><td align="center" valign="middle" >0.007</td><td align="center" valign="middle" >0.153</td><td align="center" valign="middle" >0.039</td><td align="center" valign="middle" >0.593</td></tr></tbody></table></table-wrap><p>that benzopyrene and bisphenol A are not only significantly associated with ovarian cysts. These results also show that the incidence of ovarian cysts was positively correlated to these independent risk factors, OR value reached 64.799 (P = 0.005) for benzopyrenes and 9.609 (P = 0.001) for bisphenol A. However, genistein was significantly negatively correlated with the incidence of ovarian cysts, and was an independent protective factor for ovarian cysts, with an OR value of 0.153 (P = 0.007).</p></sec><sec id="s3_5"><title>3.5. Diagnostic Performance of Benzopyrene, Bisphenol A and Genistein on Ovarian Cysts</title><p>Evaluation of the diagnostic performance of benzopyrene, bisphenol A and genistein by ROC curve, the results show that the AUC of benzopyrene and bisphenol A reached 0.765 (P = 0.0004) and 0.769 (P = 0.0003), as a molecular marker of ovarian cysts, has good predictive screening performance. Genistein had the best diagnostic performance with an AUC of 0.649, but they had potential preventive and therapeutic effects on ovarian cysts (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>Increasing evidence shows that endocrine-disrupting chemicals are involved in the development of various ovarian diseases like infertility, premature ovarian failure and abnormal sex steroid hormone levels, and also pose an increased risk for osteoporosis, depression, cardiovascular disease and early death [<xref ref-type="bibr" rid="scirp.125608-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.125608-ref18">18</xref>] . The occurrence of cardiovascular disease, depression and osteoporosis is attributed to abnormal sex steroid hormone levels caused by EDCs [<xref ref-type="bibr" rid="scirp.125608-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.125608-ref19">19</xref>] . Research has also shown that environmental exposures during fetal and early postnatal development can result in increased incidence of later life adult-onset health complications [<xref ref-type="bibr" rid="scirp.125608-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.125608-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.125608-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.125608-ref23">23</xref>] .</p><p>In this study, we evaluated the concentration levels of EDCs namely Benzo(a)pyrene, Bisphenol A and Genistein between patients with pathological ovarian cysts and normal control group. We also assessed the predictive performance and association of Benzo(a)pyrene, Bisphenol A and Genistein Flavone with pathological ovarian cysts. To our knowledge, this is the first study to evaluate these relationships.</p><p>Patients in our study were older with mean age of 36.7 years similar to other studies previously done [<xref ref-type="bibr" rid="scirp.125608-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.125608-ref25">25</xref>] . Pathological ovarian cysts were common in postmenopausal women [<xref ref-type="bibr" rid="scirp.125608-ref26">26</xref>] . Majority of the pathological ovarian cysts were endometriomas (50%) similar to other studies [<xref ref-type="bibr" rid="scirp.125608-ref24">24</xref>] .</p><p>The concentration levels of benzopyrene and bisphenol A in patients with ovarian cysts for our study were significantly higher than those in the normal control group, genistein was significantly higher in the control group. The reason could be that benzopyrene and bisphenol A may be risk factors for pathological ovarian cysts, while genistein may be a protective factor in the development of pathological ovarian cysts. Genistein is an isoflavone phytoestrogen found naturally in plants like soy beans, chickpeas, sunflower seeds and lentils [<xref ref-type="bibr" rid="scirp.125608-ref27">27</xref>] . Women are exposed to genistein primarily through ingestion of soy-based dietary products such as soy milk, tofu and soy flour [<xref ref-type="bibr" rid="scirp.125608-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.125608-ref29">29</xref>] . Bisphenol A is mainly found in polycarbonate resins namely plastic bags, bottles and packaging, particularly water and milk bottles, coated tins, particularly food and drink cans, and microwave ovenware [<xref ref-type="bibr" rid="scirp.125608-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.125608-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.125608-ref32">32</xref>] . Women easily get exposed to benzopyrenes in coal tar, cigarette smoke, wood smoke and burn food [<xref ref-type="bibr" rid="scirp.125608-ref33">33</xref>] .</p><p>Benzopyrene and bisphenol A were significantly associated with pathological ovarian cysts, incidence of pathological ovarian cysts was positively correlated to these EDCs, hence being independent risk factors for pathological ovarian cysts, the OR value reached 64.79 (P = 0.005) for benzopyrene and 9.609 (P = 0.001) for bisphenol A. However, genistein was negatively correlated with the incidence of pathological ovarian cysts, and was an independent protective factor for ovarian cysts, with an OR value of 0.153 (P = 0.007). This is similar to other previous findings as mentioned above that have shown how EDCs can cause alterations in the normal ovarian function thereby causing disease.</p><p>Evaluation of the diagnostic performance of benzopyrene, bisphenol A and genistein by ROC curve gave us an insight into how important these chemicals can be utilized as molecular biomarkers of pathological ovarian cysts. Significant results in our study have shown that the AUC for benzopyrene and bisphenol A reached 0.765 (P = 0.0004) and 0.769 (P = 0.0003) respectively. This means that benzopyrenes and bisphenol A maybe be important molecular markers of pathological ovarian cysts for predictive screening performances. Genistein had the best diagnostic performance with an AUC of 0.649, but also had potential preventive and therapeutic effects on pathological ovarian cysts.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Women are easily exposed to various kinds of EDCs which may significantly cause ovarian dysfunction from the fetal stage to adulthood. We observed that the concentration of benzopyrenes and bisphenol A was higher in patients with pathological ovarian cysts, and genistein was higher in normal controls. Benzopyrenes and bisphenol A were positively associated with pathological ovarian cysts. The evidence in our current study suggests that benzopyrene and bisphenol A might be potential novel predictive molecular biomarkers or be involved in the pathogenesis of pathological ovarian cysts while genistein may have preventive or may have inhibitory effects in the disease genesis. The present data suggest further in-depth research studies with large sample sizes for further validation of these effects. In the future, studies can be done to find specific molecular mechanisms through which benzopyrene and bisphenol A cause the pathogenesis of pathological ovarian cysts. More studies are also required to find mechanisms through which genistein inhibits pathological ovarian cyst development.</p></sec><sec id="s6"><title>Ethics Approval and Consent to Participate</title>Consent to Participate<p>Approval of this study and waiving of the participants’ informed consent due to the nature of the study were done by the ethics and research committee of the Second Affiliated Hospital of Nanjing Medical University. The data used in the study were anonymized before its use. All methods were performed in accordance with the relevant guidelines.</p></sec><sec id="s7"><title>Availability of Data and Materials</title><p>Data presented in this study can be provided upon request from the corresponding author. Due to public restrictions, data is not publicly available.</p></sec><sec id="s8"><title>Funding</title><p>This work was supported by the Chinese National Science Foundation (32271187, 32071142), Qin Lan Project of Jiangsu Province (KY520R202025), Collaborative Innovation Center for Cancer Personalized Medicine—Clinical Research Fund of Hengrui Medicine (JZ21449020210617).</p></sec><sec id="s9"><title>Authors’ Contribution</title><p>Concept and design were done by KC, XB and YXY. Statistical data analysis was done by SN. The original draft of the manuscript was done by KC. ZWW was involved in the interpretation of clinical data from the Chinese language to the English language. After the review of the manuscript content by all authors, it was agreed that the final version be submitted for publication.</p></sec><sec id="s10"><title>Acknowledgements</title><p>We are thankful to all the other members of staff at the Second Affiliated Hospital of Nanjing Medical University and other institutions involved for their input in this study.</p></sec><sec id="s11"><title>Conflicts of Interest</title><p>There are no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s12"><title>Cite this paper</title><p>Chanda, K., Wang, Z.W., Ning, S., Bin, X. and Yan, Y.X. (2023) Endocrine-Disrupting Chemicals: Possible Genesis of Ovarian Tumors. Open Journal of Obstetrics and Gynecology, 13, 1025-1037. https://doi.org/10.4236/ojog.2023.136087</p></sec><sec id="s13"><title>Abbreviations</title><p>AUC—Area Under the Curve;</p><p>EDCs—Endocrine-Disrupting Chemicals;</p><p>OR—Odds Ratio;</p><p>P-value—Probability Value;</p><p>ROC Curve—Receiver Operating Characteristic Curve;</p><p>SD—Standard Deviation;</p><p>SPSS—Statistical Package for the Social Sciences.</p></sec></body><back><ref-list><title>References</title><ref id="scirp.125608-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Greenlee, R.T., Kessel, B., Williams, C.R., et al. (2010) Prevalence, Incidence, and Natural History of Simple Ovarian Cysts among Women &gt;55 Years Old in a Large Cancer Screening Trial. American Journal of Obstetrics &amp; Gynecology, 202, 373.E1-373.E9. https://doi.org/10.1016/j.ajog.2009.11.029</mixed-citation></ref><ref id="scirp.125608-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Grimes, D.A., Jones, L.B., Lopez, L.M. and Schulz, K.F. (2014) Oral Contraceptives for Functional Ovarian Cysts. Cochrane Database of Systematic Reviews, No. 4, Article No. CD006134. https://doi.org/10.1002/14651858.CD006134.pub5</mixed-citation></ref><ref id="scirp.125608-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Liu, H., Wang, X., Lu, D., Liu, Z. and Shi, Ga. (2013) Ovarian Masses in Children and Adolescents in China: Analysis of 203 Cases. Journal of Ovarian Research, 6, Article No. 47. https://doi.org/10.1186/1757-2215-6-47</mixed-citation></ref><ref id="scirp.125608-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Pakhomov, S.P., Orlova, V.S., Verzilina, I.N., Sukhih, N.V., Nagorniy, A.V. and Matrosova, A.V. (2021) Risk Factors and Methods for Predicting Ovarian Hyperstimulation Syndrome (OHSS) in the in Vitro Fertilization. Archives of Razi Institute, 76, 1461-1468.</mixed-citation></ref><ref id="scirp.125608-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lee, S., Kim, Y.H., Kim, S.C., Joo, J.K., Seo, D.S., Kim, K.H. and Lee, K.S. (2018) The Effect of Tamoxifen Therapy on the Endometrium and Ovarian Cyst Formation in Patients with Breast Cancer. Obstetrics &amp; Gynecology Science, 61, 615-620.  
https://doi.org/10.5468/ogs.2018.61.5.615</mixed-citation></ref><ref id="scirp.125608-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Stany, M.P. and Hamilton, C.A. (2008) Benign Disorders of the Ovary. Obstetrics and Gynecology Clinics of North America, 35, 271-284. 
https://doi.org/10.1016/j.ogc.2008.03.004</mixed-citation></ref><ref id="scirp.125608-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Heling, K.-S., Chaoui, R., Kirchmair, F., Stadie, S. and Bollmann, R. (2002) Fetal Ovarian Cysts: Prenatal Diagnosis, Management and Postnatal Outcome. Ultrasound in Obstetrics &amp; Gynecology, 20, 47-50.  
https://doi.org/10.1046/j.1469-0705.2002.00725.x</mixed-citation></ref><ref id="scirp.125608-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Holt, V.L., Cushing-Haugen, K.L. and Daling, J.R. (2005) Risk of Functional Ovarian Cyst: Effects of Smoking and Marijuana Use According to Body Mass Index. American Journal of Epidemiology, 161, 520-525.  
https://doi.org/10.1093/aje/kwi080</mixed-citation></ref><ref id="scirp.125608-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Holt, V.L., Cushing-Haugen, K.L. and Daling, J.R. (2003) Oral Contraceptives, Tubal Sterilization, and Functional Ovarian Cyst Risk. Obstetrics &amp; Gynecology, 102, 252-258. https://doi.org/10.1097/00006250-200308000-00009</mixed-citation></ref><ref id="scirp.125608-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Rutkowska, A. and Rachon, D. (2014) Bisphenol A (BPA) and Its Potential Role in the Pathogenesis of the Polycystic Ovary Syndrome (PCOS). Gynecological Endocrinology, 30, 260-265. https://doi.org/10.3109/09513590.2013.871517</mixed-citation></ref><ref id="scirp.125608-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Conforti, A., Mascia, M., Cioffi, G., De Angelis, C., Coppola, G., De Rosa, P., et al. (2018) Air Pollution and Female Fertility: A Systematic Review of Literature. Reproductive Biology and Endocrinology, 16, Article No. 117.  
https://doi.org/10.1186/s12958-018-0433-z</mixed-citation></ref><ref id="scirp.125608-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Silbergeld, E.K. and Flaws, J.A. (2002) Environmental Exposures and Women’s Health. Clinical Obstetrics and Gynecology, 45, 1119-1128.  
https://doi.org/10.1097/00003081-200212000-00019</mixed-citation></ref><ref id="scirp.125608-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Craig, Z.R., Wang, W. and Flaws, J.A. (2011) Endocrine-Disrupting Chemicals in Ovarian Function: Effects on Steroidogenesis, Metabolism and Nuclear Receptor Signaling. Reproduction, 142, 633-646. https://doi.org/10.1530/REP-11-0136</mixed-citation></ref><ref id="scirp.125608-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bergman, &amp;#197;., Heindel, J., Jobling, S., Kidd, K. and Zoeller, R.T. (2012) State-of-the-Science of Endocrine Disrupting Chemicals, 2012. Toxicology Letters, 211, S3.  
https://doi.org/10.1016/j.toxlet.2012.03.020</mixed-citation></ref><ref id="scirp.125608-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Cao, X.-L., Zhang, J., Goodyer, C.G., Hayward, S., Cooke, G.M. and Curran, I.H. (2012) Bisphenol A in Human Placental and Fetal Liver Tissues Collected from Greater Montreal Area (Quebec) during 1998-2008. Chemosphere, 89, 505-511.  
https://doi.org/10.1016/j.chemosphere.2012.05.003</mixed-citation></ref><ref id="scirp.125608-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J., Choi, K., Park, J., Moon, H.-B., Choi, G., Lee, J.J., et al. (2018) Bisphenol A Distribution in Serum, Urine, Placenta, Breast Milk, and Umbilical Cord Serum in a Birth Panel of Mother-Neonate Pairs. Science of the Total Environment, 626, 1494-501.  
https://doi.org/10.1016/j.scitotenv.2017.10.042</mixed-citation></ref><ref id="scirp.125608-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Sowers, M.R. and La Pietra, M.T. (1995) Menopause: Its Epidemiology and Potential Association with Chronic Diseases. Epidemiologic Reviews, 17, 287-302.  
https://doi.org/10.1093/oxfordjournals.epirev.a036194</mixed-citation></ref><ref id="scirp.125608-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Bagur, A.C. and Mautalen, C.A. (1992) Risk for Developing Osteoporosis in Untreated Premature Menopause. Calcified Tissue International, 51, 4-7.  
https://doi.org/10.1007/BF00296207</mixed-citation></ref><ref id="scirp.125608-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sharara, F.I., Seifer, D.B. and Flaws, J.A. (1998) Environmental Toxicants and Female Reproduction. Fertility and Sterility, 70, 613-622.  
https://doi.org/10.1016/S0015-0282(98)00253-2</mixed-citation></ref><ref id="scirp.125608-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Barker, D.J.P. (2007) The Origins of the Developmental Origins Theory. Journal of Internal Medicine, 261, 412-417. https://doi.org/10.1111/j.1365-2796.2007.01809.x</mixed-citation></ref><ref id="scirp.125608-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Jirtle, R.L. and Skinner, M.K (2007) Environmental Epigenomics and Disease Susceptibility. Nature Reviews Genetics, 8, 253-262. https://doi.org/10.1038/nrg2045</mixed-citation></ref><ref id="scirp.125608-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Bale, T.L., Baram, T.Z., Brown, A.S., Goldstein, J.M., Insel, T.R., et al. (2010) Early Life Programming and Neurodevelopmental Disorders. Biological Psychiatry, 68, 314-319. https://doi.org/10.1016/j.biopsych.2010.05.028</mixed-citation></ref><ref id="scirp.125608-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Godfrey, K.M., Gluckman, P.D. and Hanson, M.A. (2010) Developmental Origins of Metabolic Disease: Life Course and Intergenerational Perspectives. Trends in Endocrinology &amp; Metabolism, 21, 199-205. https://doi.org/10.1016/j.tem.2009.12.008</mixed-citation></ref><ref id="scirp.125608-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Chanu, S.M., Dey, B., Raphael, V., Panda, S. and Khonglah, Y. (2017) Clinico-Pathological Profile of Ovarian Cysts in A Tertiary Care Hospital. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 6, 4642-4645.  
https://doi.org/10.18203/2320-1770.ijrcog20174456</mixed-citation></ref><ref id="scirp.125608-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Abduljabbar, H.S., Bukhari, Y.A., Al Hachim, E.G., Alshour, G.S., Amer, A.A., Shaikhoon, M.M. and Khojah, M.I. (2015) Review of 244 Cases of Ovarian Cysts. Saudi Medical Journal, 36, 834-838. https://doi.org/10.15537/smj.2015.7.11690</mixed-citation></ref><ref id="scirp.125608-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Hartge, P., Hayes, R., Reding, D., Sherman, M.E., Prorok, P., Schiffman, M. and Buys, S. (2000) Complex Ovarian Cysts in Postmenopausal Women Are Not Associated with Ovarian Cancer Risk Factors: Preliminary Data from the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial. American Journal of Obstetrics &amp; Gynecology, 183, 1232-1237. https://doi.org/10.1067/mob.2000.107401</mixed-citation></ref><ref id="scirp.125608-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Mazur, W. (1998) Phytoestrogen Content in Foods. Baillière’s Clinical Endocrinology and Metabolism, 12, 729-742. https://doi.org/10.1016/S0950-351X(98)80013-X</mixed-citation></ref><ref id="scirp.125608-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Khan, S.I., Zhao, J., Khan, I.A., Walker, L.A. and Dasmahapatra, A.K. (2011) Potential Utility of Natural Products as Regulators of Breast Cancer-Associated Aromatase Promoters. Reproductive Biology and Endocrinology, 9, Article No. 91.  
https://doi.org/10.1186/1477-7827-9-91</mixed-citation></ref><ref id="scirp.125608-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Reinli, K. and Block, G. (1996) Phytoestrogen Content of Foods—A Compendium of Literature Values. Nutrition and Cancer, 26, 123-148.  
https://doi.org/10.1080/01635589609514470</mixed-citation></ref><ref id="scirp.125608-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Konieczna, A., Rutkowska, A. and Rachoń, D. (2015) Health Risk of Exposure to Bisphenol A (BPA). Roczniki Państwowego Zak&amp;#322;adu Higieny (Annals of the National Institute of Hygiene), 66, 5-11.</mixed-citation></ref><ref id="scirp.125608-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Fenichel, P., Chevalier, N. and Brucker-Davis, F. (2013) Bisphenol A: An Endocrine and Metabolic Disruptor. Annales d’Endocrinologie, 74, 211-220.  
https://doi.org/10.1016/j.ando.2013.04.002</mixed-citation></ref><ref id="scirp.125608-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">FAO (2009) Bisphenol A (BPA)—Current State of Knowledge and Future Actions by WHO and FAO. International Food Safety Authorities Network (INFOSAN), Information Note No. 5/2009—Bisphenol A. Food and Agriculture Organization of the United Nations, Rome.</mixed-citation></ref><ref id="scirp.125608-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Larsson, B.K., Sahlberg, G.P., Eriksson, A.T. and Busk, L.A. (1983) Polycyclic Aromatic Hydrocarbons in Grilled Food. Journal of Agricultural and Food Chemistry, 31, 867-873. https://doi.org/10.1021/jf00118a049</mixed-citation></ref></ref-list></back></article>